Citi lowered the firm’s price target on Biomea Fusion to $22 from $45 and keeps a Buy rating on the shares. The analyst updated models in Smid-cap biotechnology following the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Etsy downgraded, Carvana upgraded: Wall Street’s top analyst calls
- Biomea Fusion assumed with an Outperform at Oppenheimer
- Biomea Fusion reports Q2 EPS ($1.03), consensus ($1.07)
- Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights